DUBLIN,
Nov. 8, 2017 /PRNewswire/
-- Allergan plc (NYSE: AGN), a leading global pharmaceutical
company, today announced its data will be presented at the annual
American Academy of Ophthalmology (AAO) meeting in New Orleans, Louisiana, November 11 – 14, 2017.
"Allergan is proud of the breadth of data being presented
at this year's AAO meeting," said David
Nicholson, executive vice president and Chief R&D
Officer at Allergan. "This clinical data underscores our commitment
to developing and bringing to market innovative treatments for
unmet diseases and conditions of the eye that impact millions of
patients globally."
The scheduled times (noted in local Central Time) and
locations of the eight Allergan data presentations at the New
Orleans Ernest N. Morial Convention Center are as
follows:
Dry Eye
- Intranasal Tear Neurostimulation for Subjects with Dry
Eye Disease: Results from Two Pivotal Clinical
Trials
-
- Date and Time: Sunday, November 12, 2017, 2:24 PM – 2:31
PM
- Session: PA022
- Location: 255-257
- Authors: E. Holland, S. Baba, M. Senchyna and M.
Holdbrook
- Total Tear Lipid and Total Protein Concentrations
Following Intranasal Tear Neurostimulation in Subjects with Dry
Eye
-
- Date and Time: Sunday, November 12, 2017, 12:45 PM – 1:45
PM
- Session: PO062
- Location: Hall C
- Authors: S. Lee, M. Senchyna, M.
Kamat and S. Baba
Retina
- Real-World Injection Patterns of Anti-VEGF Agents in
Neovascular AMD
-
- Date and Time: Sunday, November
12, 12:45 PM – 1:45 PM
- Session: PO213
- Location: Hall C
- Authors: A. Almony and J. Campbell
Glaucoma
- 24-Month Phase 1/2 Clinical Trial of Bimatoprost
Sustained-Release Implant in Glaucoma Patients
-
- Date and Time: Monday, November
13, 3:30 PM – 3:37 PM CT
- Session: PA063
- Location: 271-273
- Authors: R. Craven, T. Walters, W. Christie, D. Day, R.
Lewis, M. Goodkin, M. Chen and M. Bejanian
- A Novel OCT Iridocorneal Angle Assessment Compared to
Gonioscopy in OAG and OHT Patients
-
- Date and Time: Monday, November
13, 2017 2:36 PM –
2:43 PM CT
- Session: PA059
- Location: 271-273
- Authors: R. Craven, S. Xinghuai, H. Schenker, R.
Saltzmann, S. Lee and M. Checn
- Reduction in IOP From a Sustained-Release Bimatoprost
Ring: Pooled Results from Two Open-label Extension (OLE)
Studies
-
- Date and Time: Friday, October
13 2:00 PM – 3:15 PM CT
- Location: Room 243 – 245
- Authors: J. Brandt, H. Dubiner, K. Sall, G. Walker and C.
Semba
- Patient Reported Outcome Results in the XEN 45 Gel
Stent Pivotal Trial in Patients with Refractory
Glaucoma
-
- Date and Time: Monday, November
13, 12:45 PM – 1:45 PM CT
- Session: PO378
- Location: Hall C
- Authors: J. Panarelli, A. Sheybani, M. Stiles, R. Lewis,
M. Robinson, J. Ling, S. Lee
- Healthcare Resource Utilization Following
Trabeculectomy: An Analysis of English Hospital Episode Statistics
Data
-
- Date and Time: Sunday, November
12, 2017, 12:45 PM –
1:45 PM CT
- Session: PO108
- Location: Hall C
- Authors: A. Khawaja, I. Keyzor, K. Kishore, G. Unal and
J. Campbell
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world.
Allergan markets a portfolio of leading brands and
best-in-class products for the central nervous system, eye care,
medical aesthetics and dermatology, gastroenterology, women's
health, urology and anti-infective therapeutic
categories.
Allergan is an industry leader in Open Science, a
model of research and development, which defines our approach to
identifying and developing game-changing ideas and innovation for
better patient care. With this approach, Allergan has built one of
the broadest development pipelines in the pharmaceutical industry
with 65+ mid-to-late stage pipeline programs currently in
development.
Allergan's success is powered by our more than 18,000
global colleagues' commitment to being Bold for Life. Together, we
build bridges, power ideas, act fast and drive results for our
customers and patients around the world by always doing what is
right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to
future events or other non-historical facts are forward-looking
statements that reflect Allergan's current perspective on existing
trends and information as of the date of this release. Actual
results may differ materially from Allergan's current expectations
depending upon a number of factors affecting Allergan's business.
These factors include, among others, the difficulty of predicting
the timing or outcome of FDA approvals or actions, if any; the
impact of competitive products and pricing; market acceptance of
and continued demand for Allergan's products; difficulties or
delays in manufacturing; and other risks and uncertainties detailed
in Allergan's periodic public filings with the Securities and
Exchange Commission, including but not limited to Allergan's Annual
Report on Form 10-K for the year ended December 31, 2016 and Allergan's
Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements.
CONTACTS: Allergan:
Investors:
Daphne
Karydas
(862) 261-8006
Media:
Mark
Marmur
(862) 261-7558
Suzanne Jacobson
(201)
273-4724
View original content with
multimedia:http://www.prnewswire.com/news-releases/allergan-to-present-dynamic-eye-care-data-at-american-academy-of-ophthalmology-meeting-in-new-orleans-300551657.html
SOURCE Allergan plc